Patients’ own cells transformed into model for studying disease and developing potential treatment
Columbia University Medical Center (CUMC) researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss. The approach, the first of its kind, takes advantage of induced pluripotent stem (iPS) cell technology to transform skin cells into retinal cells, which are then used as a patient-specific model for disease study and preclinical testing.
Using this approach, researchers led by Stephen H. Tsang, MD, PhD, showed that a form of RP caused by mutations to the gene MFRP (membrane frizzled-related protein) disrupts the protein that gives retinal cells their structural integrity. They also showed that the effects of these mutations can be reversed with gene therapy. The approach could potentially be used to create personalized therapies for other forms of RP, as well as other genetic diseases. The paper was published recently in the online edition of Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy.
“The use of patient-specific cell lines for testing the efficacy of gene therapy to precisely correct a patient’s genetic deficiency provides yet another tool for advancing the field of personalized medicine,” said Dr. Tsang, the Laszlo Z. Bito Associate Professor of Ophthalmology and associate professor of pathology and cell biology.
Read more . . .
The Latest on: Personalized Gene Therapy
[google_news title=”” keyword=”Personalized Gene Therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized Gene Therapy
- TrakCel announces launch of OCELLOS Core orchestration product for early-stage personalized cell therapy developmenton May 25, 2023 at 5:48 am
TrakCel announces launch of OCELLOS Core orchestration product for early-stage personalized cell therapy development Cardiff, UK, May 25, 2023 - TrakCel, the leading and proven provider of cellular ...
- ClearPoint Neuro enters drug delivery licensing deal with UCBon May 24, 2023 at 1:25 pm
ClearPoint Neuro (Nasdaq:CLPT) announced today that it entered into a multi-year license agreement with UCB over gene therapy delivery. Solana Beach, California-based ClearPoint Neuro develops a ...
- Cell Therapy Is Poised To Break Through, If We Solve These Hurdles Nowon May 24, 2023 at 6:37 am
Thirteen years ago, the first patients were treated in a landmark cell therapy trial that was one of the biggest breakthroughs in cancer treatment. What's next?
- PTC cuts gene therapy programs, discloses PhIII fail in Friedreich's ataxia and CFO exiton May 24, 2023 at 4:40 am
PTC Therapeutics disclosed a string of disappointing news late Tuesday, revealing a Phase III flop, a pipeline reorg to cut gene therapy programs and its CFO's sudden departure. The dramatic shakeup — ...
- AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Millionon May 23, 2023 at 2:27 am
About AVROBIO Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own ...
- AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Millionon May 22, 2023 at 4:04 am
About AVROBIO Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own ...
- Coming closer to delivering on the promise of personalized breast cancer therapyon May 17, 2023 at 2:06 pm
A team led by researchers at Baylor College of Medicine is coming closer to delivering on the promise of personalized breast cancer therapy with a strategy to predict the most likely response of a ...
- ASGCT News: Siren Biotechnology Hails Universal Gene Therapy for Oncologyon May 17, 2023 at 1:16 pm
Siren Biotechnology combines AAV gene therapy and cytokine immunotherapy into a single transformative modality.
- Delivering on the promise of personalized breast cancer therapyon May 17, 2023 at 11:29 am
A team led by researchers at Baylor College of Medicine is coming closer to delivering on the promise of personalized breast cancer therapy with a strategy to ... “The first component measures how ...
- At-home DNA test kits can tell you many things. Race shouldn't be one of themon May 16, 2023 at 9:10 pm
Race is a social construct — so why are DNA test kits like the ones from 23andMe coded like they reveal biological fact about the user's racial makeup? This episode, Short Wave Scientist in Residence ...
via Bing News
